Hund Thomas J, Mohler Peter J
The Dorothy M. Davis Heart & Lung Research Institute, OH; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; Department of Biomedical Engineering, The Ohio State University College of Engineering, Columbus, OH.
The Dorothy M. Davis Heart & Lung Research Institute, OH; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; Department of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH.
Trends Cardiovasc Med. 2015 Jul;25(5):392-7. doi: 10.1016/j.tcm.2014.12.001. Epub 2014 Dec 6.
Protein phosphorylation is a central mechanism in vertebrates for the regulation of signaling. With regard to the cardiovascular system, phosphorylation of myocyte targets is critical for the regulation of excitation contraction coupling, metabolism, intracellular calcium regulation, mitochondrial activity, transcriptional regulation, and cytoskeletal dynamics. In fact, pathways that tune protein kinase signaling have been a mainstay for cardiovascular therapies for the past 60 years. The calcium/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine kinase with numerous roles in human physiology. Dysfunction in CaMKII-based signaling has been linked with a host of cardiovascular phenotypes including heart failure and arrhythmia, and CaMKII levels are elevated in human and animal disease models of heart disease. While nearly a decade has been invested in targeting CaMKII for the treatment of heart failure and arrhythmia phenotypes, to date, approaches to target the molecule for antiarrhythmic benefit have been unsuccessful for reasons that are still not entirely clear, although (1) lack of compound specificity and (2) the multitude of downstream targets are likely contributing factors. This review will provide an update on current pathways regulated by CaMKII with the goal of illustrating potential upstream regulatory mechanisms and downstream targets that may be modulated for the prevention of cardiac electrical defects. While the review will cover multiple aspects of CaMKII dysfunction in cardiovascular disease, we have given special attention to the potential of CaMKII-associated late Na(+) current as a novel therapeutic target for cardiac arrhythmia.
蛋白质磷酸化是脊椎动物信号调节的核心机制。就心血管系统而言,心肌细胞靶点的磷酸化对于调节兴奋收缩偶联、代谢、细胞内钙调节、线粒体活性、转录调节和细胞骨架动力学至关重要。事实上,在过去60年里,调节蛋白激酶信号的通路一直是心血管治疗的主要手段。钙/钙调蛋白依赖性蛋白激酶II(CaMKII)是一种多功能丝氨酸/苏氨酸激酶,在人体生理学中具有多种作用。基于CaMKII的信号传导功能障碍与包括心力衰竭和心律失常在内的一系列心血管表型有关,在人类和动物心脏病疾病模型中CaMKII水平升高。虽然近十年来一直致力于将CaMKII作为治疗心力衰竭和心律失常表型的靶点,但迄今为止,针对该分子以获得抗心律失常益处的方法尚未成功,原因仍不完全清楚,尽管(1)缺乏化合物特异性和(2)众多下游靶点可能是促成因素。本综述将提供由CaMKII调节的当前通路的最新情况,目的是阐明可能被调节以预防心脏电缺陷的潜在上游调节机制和下游靶点。虽然本综述将涵盖心血管疾病中CaMKII功能障碍的多个方面,但我们特别关注了CaMKII相关的晚钠电流作为心律失常新治疗靶点的潜力。